Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066440 | 0.89 | PRSS1 (0.61) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL6044024 | 0.85 | HCAR3 (1.00) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL6044600 | 0.84 | HCAR3 (0.97) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL11242963 | 0.84 | HCAR3 (0.97) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL11208444 | 0.84 | HCAR3 (0.97) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL6044176 | 0.84 | HCAR3 (1.00) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL3278681 | 0.82 | HCAR3 (0.78) | HCAR3MAPTPRSS1ALDH1A1 | |
| SCHEMBL2688335 | 0.81 | HCAR3 (1.00) | HCAR3MAPTALDH1A1NPC1PKM | |
| SCHEMBL28183325 | 0.81 | HCAR3 (0.86) | HCAR3MAPTPRSS1ALDH1A1NPC1 | |
| SCHEMBL1066375 | 0.79 | HCAR3 (0.77) | HCAR3MAPTALDH1A1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | HCAR3 2609/4885MAPT 494/4885PRSS1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.